Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Alrosa may pay dividends in the second half of 2023

6/19/23 ALRS

Whoosh launched a project to localize production of parts for electric scooters

6/19/23 WUSH

Tatneft shareholders could not decide on dividends

6/19/23 TATN

Moscow Exchange became a partner of the Pre-IPO platform

6/19/23 MOEX

VK intends to enter the audiobook market

6/19/23 VKCO

VKontakte will launch its own NFT-marketplace

6/19/23 VKCO

Segezha plans to create an industrial and logistics hub in Egypt

6/19/23 SGZH

VK develops TLDR service for long texts and videos

6/19/23 VKCO

Magnit reported for 3 months of 2023

6/16/23 MGNT

Magnit will buy back shares from foreign investors at a 50% discount

6/16/23 MGNT